RXRX Q4 2024 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-57.5% YoY

Gross Profit

-$8M-183.6% margin

Operating Income

-$184M-4073.8% margin

Net Income

-$179M-3966.0% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-82.7%

Cash Flow

Operating Cash Flow

-$115M

Free Cash Flow

-$117M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$414M

Stockholders' Equity

$1.0B

Cash & Equivalents

$594M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$11M	-57.5%
Gross Profit	-$8M	$743,000	-1214.8%
Operating Income	-$184M	-$99M	-85.8%
Net Income	-$179M	-$93M	-92.4%

Revenue Segments

License and Service

$19M100%

Grant

$48,0000%